Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed.

1. MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.Journal of virology · 2026
   Article
2. Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026
   Review
3. Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus.Viruses · 2025
   Review
4. Current status and research progress of oncolytic virus.Pharmaceutical science advances · 2024
   Review
5. Current approaches in glioblastoma multiforme immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
   Review
6. Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.Cancer gene therapy · 2021
   Review
7. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.International journal of molecular sciences · 2020
   Review
8. Recent advances of oncolytic virus in cancer therapy.Human vaccines & immunotherapeutics · 2020
   Review
9. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.Neuro-oncology practice · 2020
   Review
10. Delivery and Biosafety of Oncolytic Virotherapy.Frontiers in oncology · 2020
    Review
11. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.Cancers · 2018
    Review
12. Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.Frontiers in oncology · 2017
    Review
13. Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo.Cancer gene therapy · 2015
    Article
14. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Pediatric blood & cancer · 2015
    Article
15. A cross-talk network that facilitates tumor virotherapy.Nature medicine · 2015
    Article
16. Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Frontiers in immunology · 2014
    Review
17. Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.Oncolytic virotherapy · 2013
    Review
18. A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.World journal of experimental medicine · 2011
    Review
19. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Article
20. Understanding the role of tumor stem cells in glioblastoma multiforme: a review article.Journal of neuro-oncology · 2011
    Review

Corrections and comments

• Comment on
  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as